With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share

Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.

SC1902_medical aesthetics _ 740452507 _1200.jpg

Evolus Inc. will launch a fourth neurotoxin to reduce frown lines into a competitive medical aesthetics market in Spring 2019 following US FDA approval of Jeuveau (prabotulinumtoxinA). The company believes its singular focus on the beauty business will be a differentiating factor as it goes up against Allergan PLC's blockbuster Botox (onabotulinumtoxinA) and two other well-known products.

The FDA approved Jeuveau on Feb. 1 for temporary improvement in the appearance of moderate to severe glabellar lines –...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip